Home / Market News / $ACOG

$ACOG news and market catalysts

The 4 most recent market catalysts affecting $ACOG, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

4 catalysts 1 high impact 1 bullish 1 bearish Biotechnology
Oct 1, 2026 Corporate Catalyst Neutral Impact 65
Alpha Cognition Announces Data From Its 180-Day Analysis Of Its CONVERGE PRogram For Patients Receiving ZUNVEYL, Donepezil, Galantamine Or Rivastigmine
Alpha Cognition released initial 180-day data from its CONVERGE program, which is a real-world evidence study for its drug ZUNVEYL (benzgalantamine) and other acetylcholinesterase …
Aug 20, 2026 Corporate Catalyst Neutral Impact 65
B. Riley Securities Initiates Coverage On Alpha Cognition with Buy Rating, Announces Price Target of $21
B. Riley Securities analyst William Woods has initiated coverage on Alpha Cognition (ACOG) with a 'Buy' rating and a $21 price target. This event is significant because new analyst…
Aug 17, 2026 Corporate Catalyst Bullish Impact 60
HC Wainwright & Co. Maintains Buy on Alpha Cognition, Raises Price Target to $20
HC Wainwright & Co. analyst Raghuram Selvaraju maintained a 'Buy' rating on Alpha Cognition (ACOG) and raised the price target from $18 to $20. This indicates a strengthened positi…
Aug 13, 2026 Corporate Catalyst Bearish Impact 92
Alpha Cognition Q2 EPS $(0.40) Misses $(0.39) Estimate, Sales $6.092M Beat $4.384M Estimate
Alpha Cognition (ACOG) released its Q2 earnings, showing a mixed performance. While the company's loss per share of $(0.40) was slightly worse than the analyst consensus of $(0.39)…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.